Get the Stockscreener App
1.02
7.37%
0.07
After Hours:
1.02
Renovorx Inc stock is traded at $1.02, with a volume of 490.84K.
It is up +7.37% in the last 24 hours and up +8.36% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.95
Open:
$0.9677
24h Volume:
490.84K
Relative Volume:
1.32
Market Cap:
$37.38M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.7895
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
+16.62%
1M Performance:
+8.36%
6M Performance:
-25.00%
1Y Performance:
-26.09%
1-Day Range:
$0.95
$1.06
1-Week Range:
$0.8329
$1.06
52-Week Range:
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.02 | 34.82M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx receives Nasdaq notice for bid price noncompliance - MSN
RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance - TipRanks
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Aug Opening: How RenovoRx Inc stock responds to policy changesQuarterly Profit Summary & Smart Swing Trading Techniques - moha.gov.vn
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 By Investing.com - Investing.com Australia
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com India
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength - Nasdaq
Is RenovoRx Inc. stock attractive for growth ETFsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers - Smartkarma
How RenovoRx Inc. stock performs during Fed tightening cyclesIndex Update & Safe Capital Growth Stock Tips - Улправда
How RenovoRx Inc. stock reacts to inflationary pressuresJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
Will RenovoRx Inc. stock pay special dividendsJuly 2025 Final Week & AI Driven Stock Reports - Улправда
How RenovoRx Inc. stock responds to policy changesJuly 2025 Retail & Capital Efficient Trade Techniques - DonanımHaber
CEO Bagai Buys 5,000 ($4.3K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
Why RenovoRx Inc. stock could outperform in 2025Trade Risk Report & Short-Term High Return Strategies - DonanımHaber
RenovoRx Earnings Notes - Trefis
Can RenovoRx Inc. stock continue upward trendBuy Signal & Free High Accuracy Swing Entry Alerts - Улправда
RenovoRx Executive Makes a Significant Stock Purchase! - TipRanks
Chmn Agah Buys 12,000 ($10.2K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
RenovoRx CMO Ramtin Agah Buys 12,000 Shares - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) CMO-director purchases 12,000 shares at $0.85 - Stock Titan
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - Investing News Network
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO GI 2026 on Innovative Targeted Therapy for Pancreatic Cancer - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 - Stock Titan
Transcript : RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, Dec-09-2025 through Dec-10-2025 - marketscreener.com
RNXT: Six-month survival benefit and strong early revenue position the company for growth in 2026 - TradingView — Track All Markets
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Investing News Network
Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx (RNXT) Stock Analysis Report | Financials & Insights - Benzinga
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Investing News Network
RenovoRx CEO to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) CEO to detail RenovoCath updates at iAccess Alpha - Stock Titan
RenovoRx files $50M mixed securities shelf - MSN
Big Money Moves: Is RenovoRx Inc. stock attractive for growth ETFsMarket Trend Review & Safe Entry Zone Tips - BỘ NỘI VỤ
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
[Form 4] RenovoRx, Inc. Insider Trading Activity - Stock Titan
RenovoRx CMO Ramtin Agah Acquires 22,000 Shares - TradingView
Cipla Limited (CIPLA) Gets Regulatory ApprovalFinancial Sector Performance & Stay One Step Ahead of Risk Events - earlytimes.in
Is RenovoRx Inc. stock positioned for long term growthRisk Management & Reliable Volume Spike Trade Alerts - newser.com
Is RenovoRx Inc. stock a top pick in earnings seasonWeekly Profit Report & Community Driven Trade Alerts - newser.com
RenovoRx Expands Reach with RenovoCath Approval - MSN
Is RenovoRx Inc. stock dividend yield sustainablePortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-19 17:29:20 - newser.com
Tick level data insight on RenovoRx Inc. volatility2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th - Investing News Network
RenovoRx CEO Shaun Bagai to Present at Alliance Global Partners Virtual Showcase on Oncology Innovations - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Share RenovoCath, $900K YTD Revenue at AGP Showcase - Stock Titan
What drives RenovoRx Inc stock pricePrice Gap Trading Strategies & Go Beyond the Headlines With Analyst Picks - earlytimes.in
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
| Agah Ramtin | Chief Medical Officer |
Jun 05 '25 |
Buy |
1.40 |
21,000 |
29,400 |
734,460 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):